We are international
Donate
• about myeloma TEXT SIZE   
get the correct diagnosis    back

STEP 1: KNOW WHAT YOU’RE DEALING WITH - GET THE CORRECT DIAGNOSIS
03.25.13

STEP 1- REFERENCES

  1. NCCN Guidelines - Version 1, 2012

  2. Impact of Optimal Follow-up of Monoclonal Gammopathy of Undetermined Significance on early diagnosis and prevention of myeloma-related complications. Bianci, BLOOD 2010 116:2019-2025

  3. Are all Myelomas preceded by MGUS? Blade, BLOOD 2009 113:5370

  4. MGUS and SMM: Novel Biological Insights and Development of early treatment strategies. Landgren, BLOOD 2011 117:5573-5581

  5. Obesity is Associated with an Increased Risk of MGUS among Black and White Women, Landgren, BLOOD 2010 116: 1056-1059

  6. Risk of MGUS and Subsequent MM among African American & White Veterans in the United States. Landgren, BLOOD 2006 1007: 904-906

  7. Risk of Plasma Cell and Lymphoproliferative Disorders among 14621 first-degree relatives of 4458 patients of MGUS in Sweden. Landgren BLOOD 2009 114: 791-795

  8. Risk of Acute Myeloid Leukemia & Myelodysplastic Syndromes after multiple myeloma and it’s precursor disease (MGUS)  Mailankody, BLOOD 2011; 118: 4086-4092

  9. Increased Risk of Monoclonal Gammopathy in first degree relatives of patients with MM or MGUS. Vachon, BLOOD 2009, 114; 785-790

  10. A Monoclonal Gammopathy Precedes MM in Most Patients. Weiss, BLOOD 2009, 113: 5418-5422

  11. Beyond the CRAB symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma. Talamo 2010 Clinical Lymphoma, Myeloma & Leukemia.

  12. Multi-parameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Blade, 2009 Haematologica

  13. Patterns of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Various ethnic/racial groups: support for genetic factors in pathogenesis. Landgren 2009 Leukemia 23, 1691-1697

  14. Disease Associations with MGUS: A population-based study of 17,398 patients. Bida Mayo Clinic Proceedings 2009: 84(8): 685-693

  15. MGUS Significant Beyond Hematology. Letter to the Editor, Mayo Clinic Proceedings. 2009 September 84(9): 842-847

  16. Monoclonal Gammopathy of Undetermined Significance. Blade, NEJM 2006: 355-26

  17. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Fernandez de Larrea et al.  Leukemia (2012), 1-12.

  18. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Schmidt-Hieber et al.  Haematologica 2012; 98(2): 279-287

 

STEP 1- SUB-GROUP OF REFERENCES

  1. BENZENE Exposure and Multiple Myeloma. A detailed Meta-Analysis of Benzene Cohort Studies, 2006 Ann. N.Y. Academic Sc.

  2. Cancer Risk Among Firefighters: A Review and Meta-Analysis of 32 Studies, LeMasters, Ph.D. 2006 JOEM

  3. Multiple Myeloma in World Trade Center Responders: A Case Series. Moline, M.D. M.S. 2009 JOEM

 related articles